Johnson & Johnson has brought its bladder cancer drug TAR-200 to the US market, a year after its prospects were dented by a negative phase 3 readout. The novel formulation of the stalwart ...
Learn everything you need to know about iShares Russell Top 200 Growth ETF (IWY) and how it ranks compared to other funds. Research performance, expense ratio, holdings, and volatility to see if it's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results